Lupin has launched Duloxetine 40mg delayed-release capsules. The company has earlier launched Duloxetine HCl DR capsules 20 mg, 30 mg and 60 mg strengths which is the generic equivalent of Eli Lilly & Company’s (Lilly) Cymbalta delayed-release capsules 20 mg, 30 mg and 60 mg in December, 2013. Lupin has over 20 per cent market share of the same.
Cymbalta delayed-release capsules 20 mg, 30 mg and 60 mg strengths had annual US sales of approximately $1.05 billion (Brand + Generics – IMS MAT June 2015).
Lupin now has 81 products in the market. It is the market leader in 31 products marketed in the US generics market. The company is amongst the top three by market share in 55 products. (IMS Health, March 2015).
The company has 35 First-to-Files (FTF) products which includes 15 exclusive FTF opportunities.